RU2018125296A - Фармацевтические композиции для лечения диабета - Google Patents
Фармацевтические композиции для лечения диабета Download PDFInfo
- Publication number
- RU2018125296A RU2018125296A RU2018125296A RU2018125296A RU2018125296A RU 2018125296 A RU2018125296 A RU 2018125296A RU 2018125296 A RU2018125296 A RU 2018125296A RU 2018125296 A RU2018125296 A RU 2018125296A RU 2018125296 A RU2018125296 A RU 2018125296A
- Authority
- RU
- Russia
- Prior art keywords
- arg
- aib
- phe
- pglu
- glu
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 6
- 206010012601 diabetes mellitus Diseases 0.000 title claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 2
- PQBHGSGQZSOLIR-RYUDHWBXSA-N Arg-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PQBHGSGQZSOLIR-RYUDHWBXSA-N 0.000 claims 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims 1
- QHSCIWIRXWFIGH-LURJTMIESA-N (2s)-2-amino-2-methylpentanedioic acid Chemical compound OC(=O)[C@](N)(C)CCC(O)=O QHSCIWIRXWFIGH-LURJTMIESA-N 0.000 claims 1
- GPYTYOMSQHBYTK-LURJTMIESA-N (2s)-2-azaniumyl-2,3-dimethylbutanoate Chemical compound CC(C)[C@](C)([NH3+])C([O-])=O GPYTYOMSQHBYTK-LURJTMIESA-N 0.000 claims 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 claims 1
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 claims 1
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 claims 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims 1
- ARSWQPLPYROOBG-ZETCQYMHSA-N 2-methylleucine Chemical compound CC(C)C[C@](C)(N)C(O)=O ARSWQPLPYROOBG-ZETCQYMHSA-N 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- OFYAYGJCPXRNBL-LBPRGKRZSA-N naphthalen-2-yl-3-alanine Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CC=CC2=C1 OFYAYGJCPXRNBL-LBPRGKRZSA-N 0.000 claims 1
- 230000008397 ocular pathology Effects 0.000 claims 1
- 235000008729 phenylalanine Nutrition 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Применение пептида общей формулы (I):
L1-X1-X2-X3-X4,
где:
L1 представляет собой Н, или ацил, или возможно N-ацилированную и/или N-алкилированную и/или Сα-алкилированную аминокислоту, выбранную из Glu, Gln, Pro, гидрокси-Pro, Azt (азетидиновая кислота), Pip (пипеколиновая кислота), pGlu (пироглутаминовая кислота), Aib (α-амино-изомасляная кислота), Ас4с (1-аминоциклобутан-1-карбоновая кислота), Ас5с (1-аминоциклопентан-1-карбоновая кислота), Ас6с (1-аминоциклогексан-1-карбоновая кислота);
X1 и Х3, которые могут быть одинаковыми или разными, представляют собой возможно N-алкилированную и/или Сα-алкилированную основную аминокислоту, выбранную из Arg, Orn и возможно гуанидилированного Lys, и фенилаланинов, замещенных в мета или пара положениях аминогруппой или гуанидиновой группой;
Х2 представляет собой возможно N-алкилированную аминокислоту, выбранную из Glu, Lys, α-метил-лейцина, α-метил-валина, α-метил-глутаминовой кислоты, Aib, Ас4с, Ас5с, Ас6с;
Х4 представляет собой гидрофобную аминокислоту, которая амидирована или не амидирована по С-концу и возможно Сα-алкилирована, выбранную из Phe, h-Phe (гомофенилаланин), Tyr, Trp, 1-Nal (β-1-нафтил-аланин), 2-Nal (β-2-нафтил-аланин), h-1-Nal (гомо-β-1-нафтил-аланин), h-2-Nal (гомо-β-2-нафтил-аланин), Cha (циклогексил-аланин), Chg (циклогексил-глицин), Phg (фенил-глицин);
и его солей в комбинации с инсулином для лечения глазных патологий, ассоциированных с диабетом.
2. Применение по п. 1, где пептид выбран из Ac-Arg-Glu-Arg-Phe-NH2; pGlu-Arg-Glu-Arg-Tyr-OH; Glu-Arg-Glu-Arg-Phe-NH2; Ac-Arg-Glu-Arg-Tyr-NH2; Ac-Arg-Glu-Arg-Trp-NH2; Ac-Arg-Glu-N(Me)Arg-Phe-NH2; Ac-Arg-Glu-N(Me)Arg-Tyr-NH2; Ac-Arg-Glu-N(Me)Arg-Trp-NH2; pGlu-Arg-Glu-N(Me)Arg-Phe-NH2; pGlu-Arg-Glu-N(Me)Arg-Tyr-NH2; pGlu-Arg-Glu-N(Me)Arg-Trp-NH2; pGlu-Arg-Glu-Arg-Phe-NH2; pGlu-Arg-Glu-Arg-Tyr-NH2; pGlu-Arg-Glu-Arg-Trp-NH2; Ac-Arg-Aib-Arg-Phe-NH2; Ac-Arg-Aib-Arg-Tyr-NH2; Ac-Arg-Aib-Arg-Trp-NH2; Ac-Aib-Arg-Aib-Arg-Phe-NH2; Ac-Arg-Aib-N(Me)Arg-Phe-NH2; Ac-Arg-Aib-N(Me)Arg-Tyr-NH2; Ac-Arg-Aib-N(Me)Arg-Trp-NH2; pGlu-Arg-Aib-N(Me)Arg-Phe-NH2; Glu-Arg-Aib-N(Me)Arg-Tyr-NH2; pGlu-Arg-Aib-N(Me)Arg-Trp-NH2; pGlu-Arg-Aib-Arg-Phe-NH2; pGlu-Arg-Aib-Arg-Tyr-NH2; pGlu-Arg-Aib-Arg-Trp-NH2; Ac-Arg-Ac5c-Arg-Phe-NH2; Ac-Arg-Ac5c-Arg-Tyr-NH2; Ac-Arg-Ac5c-Arg-Trp-NH2; Ac-Arg-Ac5c-N(Me)Arg-Phe-NH2; Ac-Arg-Ac5c-N(Me)Arg-Tyr-NH2; Ac-Arg-Ac5c-N(Me)Arg-Trp-NH2; pGlu-Arg-Ac5c-N(Me)Arg-Phe-NH2; pGlu-Arg-Ac5c-N(Me)Arg-Tyr-NH2; pGlu-Arg-Ac5c-N(Me)Arg-Trp-NH2; pGlu-Arg-Ac5c-Arg-Phe-NH2; pGlu-Arg-Ac5c-Arg-Tyr-NH2; pGlu-Arg-Ac5c-Arg-Trp-NH2; Ac-Arg-Glu-Arg-Phe-OH; Ac-Arg-Glu-Arg-Tyr-OH; Ac-Arg-Glu-Arg-Trp-ОН; Ac-Arg-Glu-N(Me)Arg-Tyr-OH; pGlu-Arg-Glu-N(Me)Arg-Phe-OH; pGlu-Arg-Glu-Arg-Trp-ОН; Ac-Arg-Aib-Arg-Phe-OH; Ac-Arg-Aib-N(Me)Arg-Phe-OH; pGlu-Arg-Aib-N(Me)Arg-Tyr-OH; pGlu-Arg-Aib-Arg-Тrp-ОН; Ac-Arg-Ac5c-Arg-Phe-OH; Ac-Arg-Ac5c-N(Me)Arg-Tyr-OH; pGlu-Arg-Ac5c-N(Me)Arg-Trp-OH; pGlu-Arg-Ac5c-Arg-Trp-ОН; Ac-N(Me)Arg-Aib-Arg-Phe-NH2; Ac-N(Me)Arg-Aib-N(Me)Arg-Phe-NH2; Ac-Arg-Aib-N(Me)Arg-Phe-NH2; Ac-Arg-Aib-Arg-α(Me)Phe-NH2; Ac-N(Me)Arg-Aib-Arg-α(Me)Phe-NH2; Ac-N(Me)Arg-Aib-N(Me)Arg-α(Me)Phe-NH2; Ac-Arg-Aib-N(Me)Arg-α(Me)Phe-NH2; Ac-Aib-N(Me)Arg-Aib-Arg-Phe-NH2; Ac-Aib-N(Me)Arg-Aib-N(Me)Arg-Phe-NH2; Ac-Aib-Arg-Aib-N(Me)Arg-Phe-NH2; Ac-Aib-Arg-Aib-Arg-α(Me)Phe-NH2; Ac-Aib-N(Me)Arg-Aib-Arg-α(Me)Phe-NH2; Ac-Aib-N(Me)Arg-Aib-N(Me)Arg-α(Me)Phe-NH2; Ac-Aib-Arg-Aib-N(Me)Arg-α(Me)Phe-NH2 или их солей.
3. Применение по п. 1, где пептид выбран из Ac-Arg-Aib-Arg-α(Me)Phe-NH2 или Ac-Aib-Arg-Aib-Arg-α(Me)Phe-NH2 или их солей.
4. Фармацевтическая композиция, содержащая комбинацию пептида, как он определен по любому из пп. 1-3, и инсулина в форме, подходящей для раздельного, одновременного или последовательного введения.
5. Фармацевтическая композиция по п. 4 для применения в лечении осложнений диабета, в частности диабетической ретинопатии.
6. Фармацевтическая композиция по п. 4 или 5, содержащая единичную дозу пептида в диапазоне от 1 до 200 мг в комбинации со стандартными дозами инсулина.
7. Фармацевтическая композиция по п. 4 или 5, подходящая для введения подкожным, внутримышечным, внутривенным, пероральным, назальным, сублингвальным, местным, аэрозольным или трансдермальным путем или посредством ингаляции.
8. Фармацевтическая композиция по п. 7, подходящая для подкожного введения.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITUB2016A009928A ITUB20169928A1 (it) | 2016-01-12 | 2016-01-12 | Formulazioni farmaceutiche per il trattamento del diabete |
| IT102016000002015 | 2016-01-12 | ||
| PCT/EP2017/050495 WO2017121764A1 (en) | 2016-01-12 | 2017-01-11 | Pharmaceutical formulations for the treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018125296A true RU2018125296A (ru) | 2020-02-13 |
| RU2018125296A3 RU2018125296A3 (ru) | 2020-05-13 |
Family
ID=55861084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018125296A RU2018125296A (ru) | 2016-01-12 | 2017-01-11 | Фармацевтические композиции для лечения диабета |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180326014A1 (ru) |
| EP (1) | EP3402505B1 (ru) |
| JP (1) | JP2019504007A (ru) |
| KR (1) | KR20180102091A (ru) |
| CN (1) | CN108463238A (ru) |
| AU (1) | AU2017206624A1 (ru) |
| CA (1) | CA3011062A1 (ru) |
| HK (1) | HK1259373A1 (ru) |
| IL (1) | IL260512B (ru) |
| IT (1) | ITUB20169928A1 (ru) |
| RU (1) | RU2018125296A (ru) |
| WO (1) | WO2017121764A1 (ru) |
| ZA (1) | ZA201804588B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250213658A1 (en) * | 2022-04-01 | 2025-07-03 | Wake Forest University Health Sciences | Methods and formulations for intranasal delivery of insulin in the treatment of diabetic eye disease |
| IT202200007754A1 (it) | 2022-04-19 | 2023-10-19 | Iridea S R L | Nuovi composti con attivita’ farmacologica |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ661800A0 (en) * | 2000-03-31 | 2000-05-04 | Metabolic Pharmaceuticals Limited | Insulin-potentiating compounds |
| AU2002245333A1 (en) * | 2001-01-31 | 2002-08-12 | Colorado State University Research Foundation | Method for treatment of diabetic retinopathy with naturally occurring insulin-like growth factors (igfs) and igf analogs |
| DE602004004883T2 (de) * | 2003-03-28 | 2007-11-15 | Regeneron Pharmaceuticals, Inc. | Vegf-antagonisten zur behandlung von diabetes |
| ITMI20061607A1 (it) * | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | Peptidi con attivita farmacologica |
-
2016
- 2016-01-12 IT ITUB2016A009928A patent/ITUB20169928A1/it unknown
-
2017
- 2017-01-11 JP JP2018530886A patent/JP2019504007A/ja active Pending
- 2017-01-11 WO PCT/EP2017/050495 patent/WO2017121764A1/en not_active Ceased
- 2017-01-11 US US16/069,039 patent/US20180326014A1/en not_active Abandoned
- 2017-01-11 KR KR1020187019741A patent/KR20180102091A/ko not_active Withdrawn
- 2017-01-11 AU AU2017206624A patent/AU2017206624A1/en not_active Abandoned
- 2017-01-11 EP EP17701799.3A patent/EP3402505B1/en active Active
- 2017-01-11 CN CN201780006225.XA patent/CN108463238A/zh active Pending
- 2017-01-11 RU RU2018125296A patent/RU2018125296A/ru not_active Application Discontinuation
- 2017-01-11 CA CA3011062A patent/CA3011062A1/en not_active Abandoned
- 2017-01-11 HK HK19101741.9A patent/HK1259373A1/zh unknown
-
2018
- 2018-07-10 IL IL260512A patent/IL260512B/en not_active IP Right Cessation
- 2018-07-10 ZA ZA2018/04588A patent/ZA201804588B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3402505A1 (en) | 2018-11-21 |
| AU2017206624A1 (en) | 2018-07-26 |
| RU2018125296A3 (ru) | 2020-05-13 |
| KR20180102091A (ko) | 2018-09-14 |
| CN108463238A (zh) | 2018-08-28 |
| JP2019504007A (ja) | 2019-02-14 |
| EP3402505B1 (en) | 2020-06-17 |
| ITUB20169928A1 (it) | 2017-07-12 |
| IL260512B (en) | 2020-04-30 |
| ZA201804588B (en) | 2019-09-25 |
| CA3011062A1 (en) | 2017-07-20 |
| HK1259373A1 (zh) | 2019-11-29 |
| WO2017121764A1 (en) | 2017-07-20 |
| US20180326014A1 (en) | 2018-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551066A1 (en) | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant | |
| CA2704651C (en) | Use of melanocortins to treat insulin sensitivity | |
| WO2019215063A8 (en) | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
| JP2011526886A5 (ru) | ||
| DK150146B (da) | Analogifremgangsmaade til fremstilling af somatostatinanaloge hepta- eller octapeptider eller salte eller complexer deraf | |
| PE20241305A1 (es) | Analogos de amilina | |
| JP2011523935A5 (ru) | ||
| JP2016500682A5 (ru) | ||
| MX378856B (es) | Composiciones farmaceuticas parenterales acuosas estables de peptidos insulinotropicos. | |
| JP2013155195A5 (ru) | ||
| JP2016518351A5 (ru) | ||
| NZ768446A (en) | Novel glp-1 analogues | |
| JP2018504901A5 (ru) | ||
| CY1120618T1 (el) | Αναλογα αγωνιστων υποδοχεων mu οπιοειδων των ενδομορφινων | |
| EA201591529A1 (ru) | Лечение детского дефицита гормона роста человеческими аналогами гормона роста | |
| JP2016510728A5 (ru) | ||
| RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
| RU2013120135A (ru) | Глюкозозависимые инсулинотропные пептидные аналоги | |
| JP2016513107A5 (ru) | ||
| BR112013032088A2 (pt) | "polipeptídeo, composição farmacêutica e seu uso" | |
| RU2015110114A (ru) | Ангиотензин в лечении состояний головного мозга | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| HRP20160481T1 (hr) | Peptidi za cjepiva protiv alergije na brezu | |
| JP2009533355A5 (ru) | ||
| RU2018125296A (ru) | Фармацевтические композиции для лечения диабета |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200922 |